# Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

Study · id `cardio:ct-nct01182441` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01182441](<https://clinicaltrials.gov/study/NCT01182441>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01182441

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 407 participants.

## Technical summary

Registry record NCT01182441. Randomized; no masking; primary purpose treatment. Start 2010-11 (actual); primary completion 2013-01 (actual). Results posted on 2018-07-26.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 407 participants (enrolled count; ClinicalTrials.gov record NCT01182441, source copy `cardio:ctgov-nct01182441-2018-07-26`, retrieved 2026-10-26)
- Started: 2010-11 (actual) (ClinicalTrials.gov record NCT01182441, source copy `cardio:ctgov-nct01182441-2018-07-26`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01182441, source copy `cardio:ctgov-nct01182441-2018-07-26`, retrieved 2026-10-26)
- Completion: 2017-11 (actual) (ClinicalTrials.gov record NCT01182441, source copy `cardio:ctgov-nct01182441-2018-07-26`, retrieved 2026-10-26)
- Results first posted: 2018-07-26 (ClinicalTrials.gov record NCT01182441, source copy `cardio:ctgov-nct01182441-2018-07-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01182441, source copy `cardio:ctgov-nct01182441-2018-07-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01182441-2018-07-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
- Acronym: PREVAIL
- Condition: Atrial Fibrillation
- Condition: Stroke
- Intervention (Device): WATCHMAN Device
- Intervention (Drug): Warfarin
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 32f1b7dec340c07ae65c80044f3a60fbf4edf7b82944ef19847520295c8c5062
Last substantive edit: 2026-10-30
Evidence last checked: Not recorded
